Riminophenazine compounds: pharmacology and anti-neoplastic potential. (Q41457729)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

review article

1 reference

title

Riminophenazine compounds: pharmacology and anti-neoplastic potential (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

Constance E Jansen van Rensburg

2 November 2019

1 reference

ORCID Public Data File 2021

author name string

Van Rensburg CE

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

O'Sullivan JF

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

Critical Reviews in Oncology Hematology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

55-67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

A New Series of Phenazines (Rimino-Compounds) With High Antituberculosis Activity

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Prooxidative activities of 10 phenazine derivatives relative to that of clofazimine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Investigation of the structural properties of dihydrophenazines which contribute to their pro-oxidative interactions with human phagocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Anti-Tubercular Activity of Oxidation Products of Substituted o-Phenylene Diamines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine analogues active against a clofazimine-resistant organism.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Structure-activity relationships of tetramethylpiperidine-substituted phenazines against Mycobacterium leprae in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

The pharmacology, metabolism, and chemistry of clofazimine.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Tissue concentrations of clofazimine (B663) in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Adverse cutaneous reactions to antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clinical pharmacokinetics of clofazimine. A review

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Rifampin-resistant leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Mycobacterium avium complex infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

An in-vitro investigation of the susceptibility of Enterococcus faecalis to clofazimine and B669

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine in the treatment of discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine (laprene) in the treatment of discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Treatment of pyoderma gangrenosum with clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

New drugs for dermatologic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine and B669 inhibit the proliferative responses and Na+, K(+)-adenosine triphosphatase activity of human lymphocytes by a lysophospholipid-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

An in vitro comparison of the effects of the prooxidative riminophenazines clofazimine and B669 on neutrophil phospholipase A2 activity and superoxide generation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

A Potential Second Messenger Role for Unsaturated Fatty Acids: Activation of Ca2+-Dependent Protein Kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Monocyte and granulocyte-mediated tumor cell destruction. A role for the hydrogen peroxide-myeloperoxidase-chloride system

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung-cancer cell line in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Active transport of sodium and potassium ions: mechanism, function, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Electrolyte levels in neoplastic and nonneoplastic human urothelium after ouabain treatment: X-ray microanalysis of bulk hydrated samples

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Protein-liposome interactions and their relevance to the structure and function of cell membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Modulation of ATPase activity by cholesterol and synthetic ether lipids in leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

The influence of alkyl-lysophospholipids and lysophospholipid-activated macrophages on the development of metastasis of 3-Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Alpha-tocopherol prevents cyclosporin A-mediated activation of phospholipase A2 and inhibition of Na+, K(+)-adenosine triphosphatase activity in cultured hamster renal tubular cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon the growth of parent and multidrug resistant human lung cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Cyclosporins as drug resistance modifiers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Multidrug resistance during cancer chemotherapy--biotechnological solutions to a clinical problem

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Topoisomerase I in multiple drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Topoisomerase II in multiple drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

The riminophenazine agents clofazimine and B669 reverse acquired multidrug resistance in a human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Chemosensitizing interactions of clofazimine and B669 with human K562 erythroleukaemia cells with varying levels of expression of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Modulation of multidrug resistance: at the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

Determination of serum and tissue levels of phenazines including clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2896%2900229-6

7 January 2021

10.1016/S1040-8428(96)00229-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9134311%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference